Dawson James Said Dendreon News Could Be a Positive for Introgen Therapeutics (INGN)
Tweet Send to a Friend
Dawson James comments on Introgen Therapeutics (Nasdaq: INGN) following the FDA panel backing of Dendreon's (Nasdaq: DNDN) PROVENGE. Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
